Anticoagulation Forum/LinkedIn
Jun 22, 2026, 15:08
Apixaban vs. Rivaroxaban in Acute VTE – Uncoiling COBRRA and Its Clinical Implications – Anticoagulation Forum
Anticoagulation Forum shared a post on LinkedIn:
“Recording now available!
We are grateful to our expert faculty for sharing their time, and their thoughtful discussions, and insights during our recent webinar:
Apixaban vs. Rivaroxaban in Acute VTE: Uncoiling COBRRA and Its Clinical Implications
This session explored the clinical questions behind the COBRRA trial, including retrospective evidence, potential pharmacologic explanations, study design, key findings, and practical implications for frontline VTE care.
Faculty:
- Arthur Allen, PharmD
- Lana Castellucci, MD
- Steven Deitelzweig, MD
- Jori May, MD
If you missed the live webinar, want to revisit the discussion, or know a colleague who may benefit, the recording is available to watch for free on our Archived Webinars page.
-
Aug 11, 2026, 08:20Hasan Abbas Zaheer: Strengthening Universal Access to Safe Blood in Pakistan
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda